Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.23−0.46 (-5.29%)
Close on Nov 18, 2026Market cap $239.70MP/E –Yield –
Enanta Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Enanta Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$62.38M. For fiscal 2026 it was -$62.38M. The highest annual figure on record is $124.15M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Sep 30, 2026 | -$62.38M | – |
| FY2025 | Sep 30, 2025 | -$85.35M | – |
| FY2024 | Sep 30, 2024 | -$121.69M | – |
| FY2023 | Sep 30, 2023 | -$137.21M | – |
| FY2022 | Sep 30, 2022 | -$123.84M | – |
| FY2021 | Sep 30, 2021 | -$109.57M | – |
| FY2020 | Sep 30, 2020 | -$41.64M | -213.3% |
| FY2019 | Sep 30, 2019 | $36.74M | -58.4% |
| FY2018 | Sep 30, 2018 | $88.33M | +258.9% |
| FY2017 | Sep 30, 2017 | $24.61M | -20.2% |
| FY2016 | Sep 30, 2016 | $30.84M | -75.2% |
| FY2015 | Sep 30, 2015 | $124.15M | +553.9% |
| FY2014 | Sep 30, 2014 | $18.99M | +110.3% |
| FY2013 | Sep 30, 2013 | $9.03M | -57.6% |
| FY2012 | Sep 30, 2012 | $21.29M | -15.9% |
| FY2011 | Sep 30, 2011 | $25.30M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ3 2026 | Sep 30, 2026 | -$22.04M | – |
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$17.24M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$11.85M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$11.25M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$18.39M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$23.54M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$29.85M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$24.19M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$32.77M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$34.89M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$31.03M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$36.71M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$39.45M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$30.01M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$27.05M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$32.54M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$33.85M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$30.41M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$33.73M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$33.85M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$29.70M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$12.30M | -195.6% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$19.78M | -407.6% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$22.85M | -708.6% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$11.88M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $12.87M | -53.8% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $6.43M | -81.3% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $3.76M | -83.4% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$1.30M | -107.7% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $27.86M | +93.8% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $34.45M | -36.5% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $22.64M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $16.86M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $14.38M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $54.30M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$13.13M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$9.51M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$7.05M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$3.10M | – |
See a number that looks wrong?